Team:UIUC-Illinois/Project/Future/AssemblyLine
From 2012.igem.org
Line 81: | Line 81: | ||
The above is our theoretical construct involving the three aforementioned genes. | The above is our theoretical construct involving the three aforementioned genes. | ||
- | As labeled, the sequence of enzymatic activity begins at TAL, which converts the naturally present amino acid in E. Coli, Tyrosine, into p-Coumaric Acid. | + | As labeled, the sequence of enzymatic activity begins at TAL, which converts the naturally present amino acid in E. Coli, Tyrosine, into p-Coumaric Acid. A substrate could be hypothetically processed by these sequential proteins, resulting in a molecular, in vivo assembly line in E. Coli. Such an assembly line could possibly be optimized, as shown by data provided by <a href="http://www.nature.com/nature/journal/v474/n7353/full/474545c.html> Pamela Silver's Lab at Harvard Medical School</a> involving enzymatic kinetics and the favorability of an RNA scaffold, this information is also outlined by in our <a href="https://2012.igem.org/Team:UIUC-Illinois/Project/Future/Scaffold>RNA scaffold section</a>. |
+ | |||
+ | <br/><br/> | ||
+ | |||
+ | The following is a technical diagram of the stepwise modifications and production of Piceatannol from Tyrosine. | ||
+ | <br/> | ||
+ | |||
+ | <img src="https://static.igem.org/mediawiki/2012/9/92/Mechanisms.png" width=100%"> | ||
+ | <br/> | ||
+ | |||
</div> | </div> | ||
</div> | </div> |
Revision as of 16:39, 2 October 2012